Adjacent Evidence Brief: Sirtuin Biomarker Effects

Adjacent Evidence Brief: Sirtuin Biomarker Effects

Abstract

Evidence-honesty note: 11/14 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on sirtuin biomarker effects across 14 included source papers and 551 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 13 adjacent clinical sources, and 1 mechanistic or model-system source, with 0 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the immune and inflammation outcome class; null signals are summarized in the contextual adjacent evidence, deficiency prevalence, and immune and inflammation outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that sirtuin biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-sirtuin_biomarker_effects-v06-DAILY-2026-06-21T20-00-39Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-21.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• sirtuin biomarker effects aging
• sirtuin biomarker effects older adults
• sirtuin biomarker effects randomized controlled trial
• sirtuin aging
• sirtuin older adults
• sirtuin randomized controlled trial
• biomarker aging
• biomarker older adults
• biomarker randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses sirtuin biomarker effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 195 records in the receipt-candidate union, 75 were classified as source candidates and 14 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	195
Classified source candidates	75
No extractable claims	19
None-only claim binding	5
Mixed partial-or-none claim-binding candidates	22
Partial-only claim-binding candidates	2
Strict high-confidence sources	1
Admitted final sources	14

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, immune and inflammation, immune and inflammation); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=8; claims=226	no extracted directional signal in 8/8 sources	7 indirect; 1 review	limited corpus depth in this outcome class
Cardiometabolic	n=3; claims=234	unclear signal in 2/3 sources	3 indirect	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=80	positive signal in 1/2 sources	1 indirect; 1 mechanistic	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=11	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

8 included sources were assigned to this outcome class. Directional coding: null=8. Directness coding: indirect=7, review=1.

Cardiometabolic Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: indirect=3.

Population / prevalence Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Immune Outcomes

1 included source were assigned to this outcome class. Directional coding: positive=1. Directness coding: mechanistic=1.

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus for Sirtuin is dominated by observational cohort designs and preclinical experiments rather than long-term randomized trials in clinically-relevant populations. There is no long-term mortality trial in this corpus, no diabetes-prevention RCT, and no geriatric functional-outcome trial anchored to canonical thresholds such as the 0.8 m/s gait-speed cutoff (Studenski 2011) or the EWGSOP2 grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019). Consequently, the headline characterization of sirtuin biomarkers as a 'context-dependent' signal rests on indirect, indirect, and mechanistic evidence rather than on hard-outcome RCT confirmation.

Several outcome classes in the corpus are supported by only a single source, which means within-corpus replication is not possible. Because each of these outcome classes depends on one study's design choices, dosing, and population, the synthesis cannot distinguish a true null from a study-specific or measurement-specific null, and the boundary conditions of any effect remain undefined.

The population enrolled across the human sources is narrow and middle-aged-to-older, and it excludes several groups for whom sirtuin biomarker claims are often made.

Endpoint scope is a second-order limitation. It does not measure hard clinical endpoints: no mortality, no incident disability, no fracture, no hospitalization, and no adjudicated cardiovascular event. The Ioannidis 2005 caution that surrogate associations do not guarantee hard-outcome validity applies directly: the sirtuin-biomarker-to-clinical-outcome inferential chain is unbridged in this corpus, and any claim that sirtuin modulation 'works' in humans is unsupported by the sources on hand.

Finally, the corpus carries a mechanism-to-clinic gap that is structural rather than incidental. The preclinical and in-vitro sources (Cao 2022 NR gavage at 400 mg/kg/day in mice; Ding 2021 multiple-myeloma cell lines; Fu 2022 cisplatin-nephrotoxicity murine model at 8 mg/kg/week; Tsai 2021 pancreatic adenocarcinoma models with 125 mg/kg luciferin; Patyal 2024 SIRT1-v1 transfection in n = 3) supply the dominant mechanistic plausibility, while the human evidence (Wasserfurth 2021, Hwang 2020, Biscetti 2024, Sayedyousef 2025, Moin 2026, Nyarady 2020, Gonzalez-Fernandez 2019, Nowak-Szwed 2025) is almost entirely indirect, with directness flagged as 'indirect' on every source that reports it. There is no source in the corpus that traces a chain from a defined sirtuin intervention in a non-diabetic adult to a hard clinical endpoint, and the only review-design source (Moin 2026) is a meta-analysis of SIRT1 polymorphisms in diabetic nephropathy rather than of sirtuin pharmacodynamics. The synthesis therefore cannot answer whether sirtuin biomarker changes are causes, consequences, or epiphenomena of the cardiometabolic, immune, and periodontal processes the sources describe.

Conclusion

For sirtuin biomarker effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 14 included sources on Sirtuin Biomarker Effects across 5 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 14 curated reference papers, the evidence base for Sirtuin shows a context-dependent profile. Positive signals appear in: immune. Null findings dominate: contextual other, immune inflammation. The Sirtuin anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	3	null, unclear	direct interventional hard-endpoint gap
immune and inflammation	0	1	positive	direct interventional hard-endpoint gap
contextual adjacent evidence	0	8	null	direct interventional hard-endpoint gap
deficiency prevalence	0	1	null	direct interventional hard-endpoint gap
immune and inflammation	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null, unclear
P2	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: positive
P3	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 8 indirect sources; direction profile: null
P4	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P5	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Sirtuin Biomarker Effects should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Nowak-Szwed 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Wu 2022; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear.
• Wasserfurth 2021; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.051.
• Fu 2022; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null.
• Hwang 2020; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Sayedyousef 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05.
• Gonzalez-Fernandez 2019; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Moin 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05.
• Ding 2021; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Patyal 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=127.
• The sirtuin family in health and disease: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=106.
• Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=53.
• p53/sirtuin 1/NF-κB Signaling Axis in Chronic Inflammation and Maladaptive Kidney Repair After Cisplatin Nephrotoxicity: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=50.
• Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=40.
• Taurine, Sirtuin-1 and TNF- α levels in different aged adults with periodontitis: a pilot study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=39.
• Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=26.
• Deciphering the Role of Sirtuin‐1 Gene Polymorphism in Diabetic Nephropathy: A Systematic Review and Meta‐Analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=25.
• Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23.
• The Role of Sirtuin-1 Isoforms in Regulating Mitochondrial Function: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=16.
• Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=11.
• Effects of perinatal factors on sirtuin 3, 8-hydroxy-2′- deoxyguanosine, brain-derived neurotrophic factor and serotonin in cord blood and early breast milk: an observational study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=4.
• Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=1.
• Sirtuin 3 Dependent and Independent Effects of NAD + to Suppress Vascular Inflammation and Improve Endothelial Function in Mice: outcome=immune; directness=mechanistic; tier=C1; direction=positive; claims=30.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• No load-bearing cross-study disagreements were detected.

References

• Nowak-Szwed 2025. Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction. Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-03013-y. PMID: 41462250.
• Wu 2022. The sirtuin family in health and disease. Signal Transduction and Targeted Therapy, 2022. DOI: 10.1038/s41392-022-01257-8. PMID: 36581622.
• Wasserfurth 2021. Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training. Nutrients, 2021. DOI: 10.3390/nu13113824. PMID: 34836079.
• Fu 2022. p53/sirtuin 1/NF-κB Signaling Axis in Chronic Inflammation and Maladaptive Kidney Repair After Cisplatin Nephrotoxicity. Frontiers in Immunology, 2022. DOI: 10.3389/fimmu.2022.925738. PMID: 35874713.
• Hwang 2020. Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion. Biomolecules, 2020. DOI: 10.3390/biom10101414. PMID: 33036304.
• Sayedyousef 2025. Taurine, Sirtuin-1 and TNF-α levels in different aged adults with periodontitis: a pilot study. BMC Oral Health, 2025. DOI: 10.1186/s12903-025-06690-z. PMID: 40847336.
• Cao 2022. Sirtuin 3 Dependent and Independent Effects of NAD + to Suppress Vascular Inflammation and Improve Endothelial Function in Mice. Antioxidants, 2022. DOI: 10.3390/antiox11040706. PMID: 35453391.
• Gonzalez-Fernandez 2019. Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women. International Journal of Molecular Sciences, 2019. DOI: 10.3390/ijms21010295. PMID: 31906251.
• Moin 2026. Deciphering the Role of Sirtuin‐1 Gene Polymorphism in Diabetic Nephropathy: A Systematic Review and Meta‐Analysis. Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/5528647. PMID: 41624996.
• Ding 2021. Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma. Molecular Medicine Reports, 2021. DOI: 10.3892/mmr.2021.12400. PMID: 34476507.
• Patyal 2024. The Role of Sirtuin-1 Isoforms in Regulating Mitochondrial Function. Current Issues in Molecular Biology, 2024. DOI: 10.3390/cimb46080522. PMID: 39194739.
• Tsai 2021. Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency. Experimental & Molecular Medicine, 2021. DOI: 10.1038/s12276-021-00687-8. PMID: 34702956.
• Nyarady 2020. Effects of perinatal factors on sirtuin 3, 8-hydroxy-2′- deoxyguanosine, brain-derived neurotrophic factor and serotonin in cord blood and early breast milk: an observational study. International Breastfeeding Journal, 2020. DOI: 10.1186/s13006-020-00301-z. PMID: 32552911.
• Biscetti 2024. Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia. Scientific Reports, 2024. DOI: 10.1038/s41598-024-78576-z. PMID: 39506067.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.